1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
North America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Disease Indication, Procedure, and End User

North America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Disease Indication, Procedure, and End User

  • November 2022
  • 169 pages
  • ID: 6368984
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The embolotherapy market in North America is expected to grow from US$ 1,354.02 million in 2022 to US$ 2,245.73 million by 2028. It is estimated to grow at a CAGR of 8.8% from 2022 to 2028.

Rising Preference for Minimally Invasive Procedures Drives Growth of Embolotherapy Market in North America Patients increasingly prefer minimally invasive surgeries due to their various advantages such as low postoperative pain, less postoperative complications, short hospital stays, and fast recovery times.Trans Arterial Chemo Embolization (TACE) is a minimally invasive procedure that is typically used to treat hepatocellular carcinoma.

TACE is used for patients suffering from asymptomatic and unresectable liver cancer.TACE can be used to diminish the size of the tumor and make the patient eligible for liver transplantation.

It is considered an evolution from a formerly applied technique called Trans-catheter Arterial Embolization (TAE).Bleeding is a common issue in cancer patients, related to local tumor invasion, tumor angiogenesis, systemic effects of cancer, and anti-cancer treatments.

TACE involves a two-step process—selective arterial occlusion restricts the blood supply to the tumor, which causes ischemic tumor necrosis, and regional chemotherapy helps the drug remain in the area for a prolonged period, which starts causing the therapeutic effects. Prostatic artery embolization (PAE) is also a minimally invasive therapy implemented as an elective outpatient technique for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The number of patients treated with PAE has grown in recent years. Thus, the increasing preference for minimally invasive procedures is fueling the embolotherapy market growth in North America.

Market Overview
The North America embolotherapy market is segmented into the US, Canada, and Mexico.The US held the largest share of the market in 2021, owing to the growing prevalence of hepatocellular cancer and liver cancer coupled with the increasing focus of the major manufacturers on technological advancements.

Furthermore, the advanced healthcare sector of the region, the prevalence of sophisticated technological healthcare facilities.The embolotherapy market in the region is anticipated to grow significantly in the coming years owing to the rising cases of brain aneurysms.

According to the Brain Aneurysm Foundation’s report, ~6 million people have unruptured brain aneurysms in the US.Also, the annual rate of rupture is nearly 8–10 per 100,000 people; ~30,000 people in the country suffer from a brain aneurysm rupture.

In addition, about 4 out of 7 people who recover from a ruptured brain aneurysm are likely to suffer from the disabilities. This neurological disorder generally affects people who are in the age group of 35–60 years. However, the brain aneurysm can also be seen in children, and women in the country suffer more than men.
North America Embolotherapy Market Revenue and Forecast to 2028 (US$ Million)

North America Embolotherapy Market Segmentation

The North America embolotherapy market is segmented on the basis of product, disease indication, procedure, end user, and country.
Based on product, the North America embolotherapy market is bifurcated into embolic agents and support devices.The embolic agents segment held a larger market share in 2022.

Based on disease indication, the North America embolotherapy market is segmented into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others.The cancer segment held the largest market share in 2022.

Based on procedure, the North America embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE).The transcatheter arterial embolization (TAE) segment held the largest market share in 2022.

Based on end user, the North America embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the North America embolotherapy market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. Abbott Laboratories, Boston Scientific Corporation, Cook Medical LLC, Johnson & Johnson, Medtronic, Acandis GmbH, Balt USA LLC, Stryker Corporation, Guerbet LLC, and Terumo Corporation are among the leading companies operating in the embolotherapy market in North America.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Europe Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Disease Indication, Procedure, and End User

  • $ 3000
  • November 2022
  • 191 pages

The embolotherapy market in Europe is expected to grow from US$ 1,050.81 million in 2022 to US$ 1,638.92 million by 2028. It is estimated to grow at a CAGR of 7.7% from 2022 to 2028. Rising Prevalence ...

  • Europe
  • Cancer
  • Pathology
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure

Anti-Tumor Drugs Markets in China $ 4000 October 2022


ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on